Charles River Laboratories CRL Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Business | ||||||
| DSA | $2.41B-1.3% | $2.4B-2.0% | $2.41B-2.4% | $2.43B-3.7% | $2.44B-4.7% | |
| Manufacturing | $778.46M+2.1% | $766.41M-0.4% | $764.96M-0.2% | $771.14M+3.5% | $762.62M+3.1% | |
| RMS | $841.38M+2.4% | $846.08M+2.0% | $844.08M+2.8% | $828.43M+2.3% | $821.54M+1.0% | |
| Total by Business | ||||||
| DSA | $41.02M-18.6% | $51.68M+31.4% | $53.37M+97.1% | $62.71M+137% | $50.4M+122% | |
| Manufacturing | $15.01M+0.4% | $18.26M+41.8% | $17M+46.1% | $19.74M+173% | $14.95M+105% | |
| RMS | $34.92M-8.0% | $18.71M-57.4% | $36M+43.5% | $35.14M+66.6% | $37.95M+249% | |
| Cost of revenue (excluding amortization of intangible assets) by Business | ||||||
| DSA | $1.7B+0.1% | $1.69B-0.7% | $1.7B+2.8% | $1.7B+1.3% | $1.7B+1.0% | |
| Manufacturing | $434.89M-1.1% | $429.84M-2.4% | $435.95M-2.0% | $439.16M+1.2% | $439.63M+0.9% | |
| RMS | $590.92M+2.1% | $576.25M-0.7% | $589.15M+7.0% | $579.06M+7.4% | $578.86M+10.5% | |
| Operating Income (Loss) by Business | ||||||
| DSA | $434.48M+3.0% | $424.56M-4.1% | $402.75M-20.4% | $406.03M-22.9% | $421.62M-23.3% | |
| Manufacturing | -$128.83M-13.2% | -$184.28M-158% | -$139.19M-195% | -$138.92M-205% | -$113.75M-195% | |
| SG&A by Business | ||||||
| DSA | $222M-13.8% | $239.77M-3.7% | $256.33M+2.8% | $263.32M+5.6% | $257.53M-0.4% | |
| Manufacturing | $137.78M+2.8% | $142.1M+7.0% | $132.41M+1.0% | $132.59M-1.6% | $133.99M-3.9% | |
| RMS | $78.92M-24.3% | $101.53M-8.5% | $103.55M-5.6% | $105.07M-4.3% | $104.3M-5.0% | |
| Foreign exchange by Business | ||||||
| RMS | $1.69M-86.3% | $14.1M+2,022% | $12.63M— | $13.23M— | $12.35M— | |
| Goodwill, Written off Related to Sale of Business Unit by Business | ||||||
| Manufacturing | $0— | $0— | —— | —— | —— | |
| RMS | $0— | $0— | —— | —— | —— | |
| Capital Expenditures by Business | ||||||
| DSA | $135.95M+19.3% | $132.96M+3.6% | $115.91M-17.6% | $112.97M-29.3% | $113.92M-39.6% | |
| Manufacturing | $30.42M-35.2% | $41.43M+7.6% | $43.95M+11.6% | $47.5M+5.6% | $46.92M+3.7% | |
| RMS | $43.12M-16.1% | $38.84M-39.4% | $41.69M-22.2% | $45.7M-17.8% | $51.38M-4.5% | |
| D&A by Business | ||||||
| DSA | $171.86M-8.3% | $174.03M-8.9% | $178.52M-4.2% | $182.27M-0.2% | $187.42M+5.3% | |
| Manufacturing | $93.99M-24.7% | $140.22M+55.9% | $157.13M+95.2% | $160.05M+99.4% | $124.78M+56.6% | |
| RMS | $75.45M-2.6% | $81.08M+9.8% | $84.17M+25.1% | $80.62M+28.4% | $77.45M+28.6% | |
| Intangible Amortization by Business | ||||||
| DSA | $49.7M-17.0% | $52.55M-15.9% | $54.83M-15.3% | $57.36M-14.0% | $59.89M-12.9% | |
| Manufacturing | $60.65M-30.9% | $104.78M+99.7% | $120.78M+178% | $123.32M+181% | $87.76M+98.7% | |
| RMS | $18.81M-20.0% | $21.74M-7.5% | $23.66M+2.3% | $23.6M+4.4% | $23.52M+6.0% | |
| Goodwill, impaired, accumulated impairment loss by Business | ||||||
| DSA | $4B0.0% | $4B0.0% | $4B— | $4B— | $4B— | |
| Manufacturing | $1.19B— | $1.03B— | —— | —— | —— | |
| Total Revenue by Geography | ||||||
| Asia Pacific | $218.56M+13.2% | $205.02M+4.1% | $203.89M+2.4% | $197.24M+1.5% | $193.12M-5.2% | |
| Canada | $485.24M-2.4% | $501.03M+3.9% | $497.11M+0.9% | $507.39M+2.6% | $497.05M+2.0% | |
| Europe | $1.12B+4.9% | $1.1B+2.3% | $1.09B0.0% | $1.08B-0.8% | $1.07B-1.9% | |
| Other | $57.59M+9.2% | $64.87M+22.8% | $65.2M+45.5% | $55.38M+54.7% | $52.74M+71.3% | |
| U.S. | $2.15B-3.0% | $2.14B-4.4% | $2.17B-3.0% | $2.19B-3.3% | $2.21B-3.9% | |
| Long-Lived Assets by Geography | ||||||
| Asia Pacific | $248.45M-8.1% | $252.26M-8.9% | $256.49M-10.1% | $265.76M— | $270.45M— | |
| Canada | $636M+5.5% | $622.2M+2.4% | $605.9M-1.9% | $605.21M— | $602.58M— | |
| Europe | $1.82B+8.7% | $1.79B+8.8% | $1.74B+5.8% | $1.72B— | $1.67B— | |
| Other | $165.57M+13.0% | $161.04M+11.9% | $155.19M+8.1% | $151.2M— | $146.5M— | |
| U.S. | $3.5B-6.9% | $3.61B-5.0% | $3.63B-4.9% | $3.7B— | $3.75B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Charles River Laboratories break its business down?
- Charles River Laboratories (CRL) reports total revenue by business across 3 parts — DSA, Manufacturing and RMS. Each is extracted from the segment footnotes and tracked over time.
- Where does Charles River Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Charles River Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
